Hezi Zhang
Hezi Zhang has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Lichao Cao
School of Medicine, Northwest University, Xi’an, China
10 shared publicationsYing Ba
Department of Research and Development, Shenzhen Nucleus Gene Technology Co., Ltd., Shenzhen, China
10 shared publicationsShenrui Zhang
Shenzhen Nucleus Gene Technology Co., Ltd., Shenzhen, 518071, China
7 shared publicationsFang Chen
Shenzhen Nucleus Gene Technology Co., Ltd., Shenzhen, 518071, China
6 shared publicationsJiahao Zhang
Shenzhen Nucleus Gene Technology Co., Ltd., Shenzhen, Guangdong Province, China
2 shared publications- Jin Yang
Northwest University
2 shared publications
Latest Publications
- Open Access
- 5 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1686461
TRPM6 acts as a prognostic biomarker and mediates Mg2+ dependent tumor suppression in colon adenocarcinoma
Introduction: Colon adenocarcinoma (COAD) is a malignant neoplasm derived from colonic epithelial cells with poor prognosis in advanced stages. This study aimed to identify critical molecular regulators of COAD and develop robust biomarkers for prognosis and therapy. Methods: Transcriptome data from public databases were analyzed: differential expression of TRPM family genes in COAD and pan-cancer pathogenic associations of TRPM6 were assessed via the Wilcoxon test, with analyses of consensus molecular subtypes, clinical relevance, and survival also performed. TRPM6-regulated differentially expressed genes (DEGs) were identified for functional enrichment, and immune/tumor microenvironment correlations were evaluated using the Spearman test. In vitro , HCT116 and SW480 cells were transfected with TRPM6 siRNAs, with proliferation (CCK-8), migration (Transwell), and marker expression (RT-qPCR) assessed. Results and Discussion: The study showed TRPM family genes, particularly TRPM4 and TRPM6, had differential expression across COAD subtypes/stages, with high expression correlating with favorable prognosis. TRPM6 regulates cancers via neural pathways, associates with immune/tumor microenvironments, and has pan-cancer diagnostic value. TRPM6 knockdown promoted colon cancer cell proliferation and migration, while concurrent TRPM6 knockdown and high Mg 2+ treatment attenuated Mg 2+ -mediated tumor suppression. These findings highlight TRPM6 as a pivotal mediator of Mg 2+ functions and a valuable candidate for COAD prognostic classification and therapeutic intervention, providing a foundation for future studies on its regulatory roles in tumor progression and Mg 2+ -based therapies.
- 5 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1686461
Open AccessTRPM6 acts as a prognostic biomarker and mediates Mg2+ dependent tumor suppression in colon adenocarcinoma
Introduction: Colon adenocarcinoma (COAD) is a malignant neoplasm derived from colonic epithelial cells with poor prognosis in advanced stages. This study aimed to identify critical molecular regulators of COAD and develop robust biomarkers for prognosis and therapy. Methods: Transcriptome data from public databases were analyzed: differential expression of TRPM family genes in COAD and pan-cancer pathogenic associations of TRPM6 were assessed via the Wilcoxon test, with analyses of consensus molecular subtypes, clinical relevance, and survival also performed. TRPM6-regulated differentially expressed genes (DEGs) were identified for functional enrichment, and immune/tumor microenvironment correlations were evaluated using the Spearman test. In vitro , HCT116 and SW480 cells were transfected with TRPM6 siRNAs, with proliferation (CCK-8), migration (Transwell), and marker expression (RT-qPCR) assessed. Results and Discussion: The study showed TRPM family genes, particularly TRPM4 and TRPM6, had differential expression across COAD subtypes/stages, with high expression correlating with favorable prognosis. TRPM6 regulates cancers via neural pathways, associates with immune/tumor microenvironments, and has pan-cancer diagnostic value. TRPM6 knockdown promoted colon cancer cell proliferation and migration, while concurrent TRPM6 knockdown and high Mg 2+ treatment attenuated Mg 2+ -mediated tumor suppression. These findings highlight TRPM6 as a pivotal mediator of Mg 2+ functions and a valuable candidate for COAD prognostic classification and therapeutic intervention, providing a foundation for future studies on its regulatory roles in tumor progression and Mg 2+ -based therapies.
- Open Access
- 10 November 2025
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 16, 1650544
Unveiling disulfidptosis-linked lncRNA signatures: insights into the immune microenvironment and drug responsiveness in oral squamous cell carcinoma
Objectives: Oral squamous cell carcinoma (OSCC) has a highly incidence rate and mortality rate all over the world. Hitherto, there are limited studies on survival significance between disulfidptosis-related lncRNAs (DRLs) and OSCC. Therefore, this study was conducted to investigate the potential role of these DRLs and provide some theoretical support in the clinical treatment of OSCC. Methods: OSCC-related lncRNAs and disulfidptosis-related genes (DRGs) were retrieved from public databases. Using Pearson correlation, machine learning, and expression profiling, we identified differentially expressed DRLs (DE-DRLs), developed a DE-DRLs-based risk model and independent prognostic nomogram, performed immunological and tumor microenvironment analyses to explore DE-DRLs regulatory mechanisms, predicted potential drugs for OSCC, and validated bioinformatics findings. Results: In this study, 9 DE-DRLs were identified that correlated with OSCC. The risk model and nomogram showed good clinical utility for assessing the likelihood of OSCC occurrence. Patients exhibiting elevated levels of eosinophils, activated natural killer (NK) cells, or naïve CD4 + T cells experienced significantly poorer overall survival (OS), and patients with high tumor mutational burden (TMB) had worse prognosis. 12 drugs were identified for OSCC treatment, such as BMS-754807_2171 and Foretinib_2040. Conclusion: Our study identified 9 DE-DRLs correlated with OSCC, which will be a personalized prediction tool for prognosis and immune responses in OSCC patients.
- 10 November 2025
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 16, 1650544
Open AccessUnveiling disulfidptosis-linked lncRNA signatures: insights into the immune microenvironment and drug responsiveness in oral squamous cell carcinoma
Objectives: Oral squamous cell carcinoma (OSCC) has a highly incidence rate and mortality rate all over the world. Hitherto, there are limited studies on survival significance between disulfidptosis-related lncRNAs (DRLs) and OSCC. Therefore, this study was conducted to investigate the potential role of these DRLs and provide some theoretical support in the clinical treatment of OSCC. Methods: OSCC-related lncRNAs and disulfidptosis-related genes (DRGs) were retrieved from public databases. Using Pearson correlation, machine learning, and expression profiling, we identified differentially expressed DRLs (DE-DRLs), developed a DE-DRLs-based risk model and independent prognostic nomogram, performed immunological and tumor microenvironment analyses to explore DE-DRLs regulatory mechanisms, predicted potential drugs for OSCC, and validated bioinformatics findings. Results: In this study, 9 DE-DRLs were identified that correlated with OSCC. The risk model and nomogram showed good clinical utility for assessing the likelihood of OSCC occurrence. Patients exhibiting elevated levels of eosinophils, activated natural killer (NK) cells, or naïve CD4 + T cells experienced significantly poorer overall survival (OS), and patients with high tumor mutational burden (TMB) had worse prognosis. 12 drugs were identified for OSCC treatment, such as BMS-754807_2171 and Foretinib_2040. Conclusion: Our study identified 9 DE-DRLs correlated with OSCC, which will be a personalized prediction tool for prognosis and immune responses in OSCC patients.
- Open Access
- 1 January 2025
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 41, 101912
The prognostic significance of epoxide hydrolases in colorectal cancer
- 1 January 2025
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 41, 101912
Open AccessThe prognostic significance of epoxide hydrolases in colorectal cancer
- Open Access
- 2 September 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1450135
Prognostic cellular senescence-related lncRNAs patterns to predict clinical outcome and immune response in colon cancer
Background: Cellular senescence (CS) is believed to be a major factor in the evolution of cancer. However, CS-related lncRNAs (CSRLs) involved in colon cancer regulation are not fully understood. Our goal was to create a novel CSRLs prognostic model for predicting prognosis and immunotherapy and exploring its potential molecular function in colon cancer.Methods: The mRNA sequencing data and relevant clinical information of GDC TCGA Colon Cancer (TCGA-COAD) were obtained from UCSC Xena platform, and CS-associated genes was acquired from the CellAge website. Pearson correlation analysis was used to identify CSRLs. Then we used Kaplan–Meier survival curve analysis and univariate Cox analysis to acquire prognostic CSRL. Next, we created a CSRLs prognostic model using LASSO and multivariate Cox analysis, and evaluated its prognostic power by Kaplan–Meier and ROC curve analysis. Besides, we explored the difference in tumor microenvironment, somatic mutation, immunotherapy, and drug sensitivity between high-risk and low-risk groups. Finally, we verified the functions of MYOSLID in cell experiments.Results: Three CSRLs (AC025165.1, LINC02257 and MYOSLID) were identified as prognostic CSRLs. The prognostic model exhibited a powerful predictive ability for overall survival and clinicopathological features in colon cancer. Moreover, there was a significant difference in the proportion of immune cells and the expression of immunosuppressive point biomarkers between the different groups. The high-risk group benefited from the chemotherapy drugs, such as Teniposide and Mitoxantrone. Finally, cell proliferation and CS were suppressed after MYOSLID knockdown.Conclusion: CSRLs are promising biomarkers to forecast survival and therapeutic responses in colon cancer patients. Furthermore, MYOSLID, one of 3-CSRLs in the prognostic model, could dramatically regulate the proliferation and CS of colon cancer.
- 2 September 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1450135
Open AccessPrognostic cellular senescence-related lncRNAs patterns to predict clinical outcome and immune response in colon cancer
Background: Cellular senescence (CS) is believed to be a major factor in the evolution of cancer. However, CS-related lncRNAs (CSRLs) involved in colon cancer regulation are not fully understood. Our goal was to create a novel CSRLs prognostic model for predicting prognosis and immunotherapy and exploring its potential molecular function in colon cancer.Methods: The mRNA sequencing data and relevant clinical information of GDC TCGA Colon Cancer (TCGA-COAD) were obtained from UCSC Xena platform, and CS-associated genes was acquired from the CellAge website. Pearson correlation analysis was used to identify CSRLs. Then we used Kaplan–Meier survival curve analysis and univariate Cox analysis to acquire prognostic CSRL. Next, we created a CSRLs prognostic model using LASSO and multivariate Cox analysis, and evaluated its prognostic power by Kaplan–Meier and ROC curve analysis. Besides, we explored the difference in tumor microenvironment, somatic mutation, immunotherapy, and drug sensitivity between high-risk and low-risk groups. Finally, we verified the functions of MYOSLID in cell experiments.Results: Three CSRLs (AC025165.1, LINC02257 and MYOSLID) were identified as prognostic CSRLs. The prognostic model exhibited a powerful predictive ability for overall survival and clinicopathological features in colon cancer. Moreover, there was a significant difference in the proportion of immune cells and the expression of immunosuppressive point biomarkers between the different groups. The high-risk group benefited from the chemotherapy drugs, such as Teniposide and Mitoxantrone. Finally, cell proliferation and CS were suppressed after MYOSLID knockdown.Conclusion: CSRLs are promising biomarkers to forecast survival and therapeutic responses in colon cancer patients. Furthermore, MYOSLID, one of 3-CSRLs in the prognostic model, could dramatically regulate the proliferation and CS of colon cancer.
- Open Access
- 6 August 2024
- Published by Impact Journals, LLC in Aging
- Vol. 16 (15) , 11606-11625
Exploration of bacterial lipopolysaccharide-related genes signature based on T cells for predicting prognosis in colorectal cancer
Purpose: The intratumoral microorganisms participates in the progression and immunotherapy of colorectal cancer (CRC). However, due to technical limitations, the impact of microorganisms on CRC has not been fully understood. Therefore, we conducted a systematic analysis of relationship between bacterial lipopolysaccharide (LPS)-associated genes and immune cells to explore new biomarkers for predicting the prognosis of CRC. Methods: The single-cell RNA sequencing data and the Comparative Toxicogenomics Database were used to screen T cells-associated LPS-related genes (TALRGs). Then, we established and validated the TALRGs risk signature in The Cancer Genome Atlas Colon Adenocarcinoma (TCGA-COAD) cohort and GSE39582 cohort. Besides, we compared the differences in tumor-infiltrating immune cell types, immunotherapeutic response, somatic mutation profiles, and tumor mutation burden (TMB) between high-risk group and low-risk group. In addition, the immunotherapeutic cohort (Imvigor210) treated with an anti-PD-L1 agent was performed to explore the potential value of the TALRGs signature on immunotherapy. Results: Five prognostic TALRGs were identified and selected to build the prognostic model. The high-risk group had poor prognosis in both TCGA-COAD cohort (P < 0.0001) and GSE39582 cohort (P = 0.00019). The areas under the curves (AUCs) of TALRGs signature were calculated (TCGA-COAD cohort: 0.624 at 1 years, 0.639 at 3 years, 0.648 at 5 years; anti-PD-L1 cohort was 0.59). The high-risk group had advanced pathological stages and higher TMN stages in both TCGA-COAD cohort and GSE39582 cohort. The high-risk group had the higher infiltration of immunosuppressive cells, the expressions of immune checkpoint molecules, the IC50 values of chemotherapy drugs, and TP53 mutation rate (P < 0.05). In addition, patients with high TMB had worse prognosis (P < 0.05). Furthermore, the Imvigor210 also showed patients with high-risk scores had poor prognosis (platinum-treated cohort: P = 0.0032; non-platinum-treated cohort: P = 0.00017). Conclusions: Microorganisms are closely related to the tumor microenvironment to influence the progression and immune response of CRC via stimulating T cells through LPS-related genes. The TALRGs signature contributed to predict the prognosis and immunotherapy of CRC, and became new therapeutic targets and biomarkers of CRC.
- 6 August 2024
- Published by Impact Journals, LLC in Aging
- Vol. 16 (15) , 11606-11625
Open AccessExploration of bacterial lipopolysaccharide-related genes signature based on T cells for predicting prognosis in colorectal cancer
Purpose: The intratumoral microorganisms participates in the progression and immunotherapy of colorectal cancer (CRC). However, due to technical limitations, the impact of microorganisms on CRC has not been fully understood. Therefore, we conducted a systematic analysis of relationship between bacterial lipopolysaccharide (LPS)-associated genes and immune cells to explore new biomarkers for predicting the prognosis of CRC. Methods: The single-cell RNA sequencing data and the Comparative Toxicogenomics Database were used to screen T cells-associated LPS-related genes (TALRGs). Then, we established and validated the TALRGs risk signature in The Cancer Genome Atlas Colon Adenocarcinoma (TCGA-COAD) cohort and GSE39582 cohort. Besides, we compared the differences in tumor-infiltrating immune cell types, immunotherapeutic response, somatic mutation profiles, and tumor mutation burden (TMB) between high-risk group and low-risk group. In addition, the immunotherapeutic cohort (Imvigor210) treated with an anti-PD-L1 agent was performed to explore the potential value of the TALRGs signature on immunotherapy. Results: Five prognostic TALRGs were identified and selected to build the prognostic model. The high-risk group had poor prognosis in both TCGA-COAD cohort (P < 0.0001) and GSE39582 cohort (P = 0.00019). The areas under the curves (AUCs) of TALRGs signature were calculated (TCGA-COAD cohort: 0.624 at 1 years, 0.639 at 3 years, 0.648 at 5 years; anti-PD-L1 cohort was 0.59). The high-risk group had advanced pathological stages and higher TMN stages in both TCGA-COAD cohort and GSE39582 cohort. The high-risk group had the higher infiltration of immunosuppressive cells, the expressions of immune checkpoint molecules, the IC50 values of chemotherapy drugs, and TP53 mutation rate (P < 0.05). In addition, patients with high TMB had worse prognosis (P < 0.05). Furthermore, the Imvigor210 also showed patients with high-risk scores had poor prognosis (platinum-treated cohort: P = 0.0032; non-platinum-treated cohort: P = 0.00017). Conclusions: Microorganisms are closely related to the tumor microenvironment to influence the progression and immune response of CRC via stimulating T cells through LPS-related genes. The TALRGs signature contributed to predict the prognosis and immunotherapy of CRC, and became new therapeutic targets and biomarkers of CRC.
- Open Access
- 6 June 2024
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 15, 1413434
Direct prediction of antimicrobial resistance in Pseudomonas aeruginosa by metagenomic next-generation sequencing
Objective: Pseudomonas aeruginosa has strong drug resistance and can tolerate a variety of antibiotics, which is a major problem in the management of antibiotic-resistant infections. Direct prediction of multi-drug resistance (MDR) resistance phenotypes of P. aeruginosa isolates and clinical samples by genotype is helpful for timely antibiotic treatment.Methods: In the study, whole genome sequencing (WGS) data of 494 P. aeruginosa isolates were used to screen key anti-microbial resistance (AMR)-associated genes related to imipenem (IPM), meropenem (MEM), piperacillin/tazobactam (TZP), and levofloxacin (LVFX) resistance in P. aeruginosa by comparing genes with copy number differences between resistance and sensitive strains. Subsequently, for the direct prediction of the resistance of P. aeruginosa to four antibiotics by the AMR-associated features screened, we collected 74 P. aeruginosa positive sputum samples to sequence by metagenomics next-generation sequencing (mNGS), of which 1 sample with low quality was eliminated. Then, we constructed the resistance prediction model.Results: We identified 93, 88, 80, 140 AMR-associated features for IPM, MEM, TZP, and LVFX resistance in P. aeruginosa. The relative abundance of AMR-associated genes was obtained by matching mNGS and WGS data. The top 20 features with importance degree for IPM, MEM, TZP, and LVFX resistance were used to model, respectively. Then, we used the random forest algorithm to construct resistance prediction models of P. aeruginosa, in which the areas under the curves of the IPM, MEM, TZP, and LVFX resistance prediction models were all greater than 0.8, suggesting these resistance prediction models had good performance.Conclusion: In summary, mNGS can predict the resistance of P. aeruginosa by directly detecting AMR-associated genes, which provides a reference for rapid clinical detection of drug resistance of pathogenic bacteria.
- 6 June 2024
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 15, 1413434
Open AccessDirect prediction of antimicrobial resistance in Pseudomonas aeruginosa by metagenomic next-generation sequencing
Objective: Pseudomonas aeruginosa has strong drug resistance and can tolerate a variety of antibiotics, which is a major problem in the management of antibiotic-resistant infections. Direct prediction of multi-drug resistance (MDR) resistance phenotypes of P. aeruginosa isolates and clinical samples by genotype is helpful for timely antibiotic treatment.Methods: In the study, whole genome sequencing (WGS) data of 494 P. aeruginosa isolates were used to screen key anti-microbial resistance (AMR)-associated genes related to imipenem (IPM), meropenem (MEM), piperacillin/tazobactam (TZP), and levofloxacin (LVFX) resistance in P. aeruginosa by comparing genes with copy number differences between resistance and sensitive strains. Subsequently, for the direct prediction of the resistance of P. aeruginosa to four antibiotics by the AMR-associated features screened, we collected 74 P. aeruginosa positive sputum samples to sequence by metagenomics next-generation sequencing (mNGS), of which 1 sample with low quality was eliminated. Then, we constructed the resistance prediction model.Results: We identified 93, 88, 80, 140 AMR-associated features for IPM, MEM, TZP, and LVFX resistance in P. aeruginosa. The relative abundance of AMR-associated genes was obtained by matching mNGS and WGS data. The top 20 features with importance degree for IPM, MEM, TZP, and LVFX resistance were used to model, respectively. Then, we used the random forest algorithm to construct resistance prediction models of P. aeruginosa, in which the areas under the curves of the IPM, MEM, TZP, and LVFX resistance prediction models were all greater than 0.8, suggesting these resistance prediction models had good performance.Conclusion: In summary, mNGS can predict the resistance of P. aeruginosa by directly detecting AMR-associated genes, which provides a reference for rapid clinical detection of drug resistance of pathogenic bacteria.
- Open Access
Identifying important microbial biomarkers for the diagnosis of colon cancer using a random forest approach
- Open Access
- 24 July 2023
- Published by Impact Journals, LLC in Aging
- Vol. 15 (14) , 7084-7097
Severe pneumonia induces immunosenescence of T cells in the lung of mice
Background: In this study, we compared the prognosis, tumor immune microenvironment (TIM), and drug treatment response between left-sided (LCC) and right-sided (RCC) colon cancer to predict outcomes in patients with LCC and RCC. Methods: Based on identified differentially expressed genes and using single-cell RNA sequencing data, we constructed and validated a prognostic model for LCC and RCC patients in the TCGA-COAD cohort and GSE103479 cohort. Moreover, we compared the differences of TIM characteristics and drug treatment response between LCC and RCC patients. Results: We constructed and validated a five-gene prognostic model for LCC patients and a four-gene prognostic model for RCC patients, and both showed excellent performance. The RCC patients with higher risk scores were significantly associated with greater metastasis (P = 2.6×10-5), N stage (P = 0.012), advanced pathological stage (P = 1.4×10-4), and more stable microsatellite status (P = 0.007) but not T stage (P = 0.200). For LCC patients, the risk scores were not significantly associated with tumor stage and microsatellite status (P > 0.05). Additionally, immune infiltration by CD8 and regulatory T cells and M0, M1, and M2 macrophages differed significantly between LCC and RCC patients (P < 0.05). APC and TP53 mutations were significantly more common in LCC patients (P < 0.05). In contrast, KRAS, SYNE1, and MUC16 mutations were significantly more common in RCC patients (P < 0.05). In addition, tumor mutation burden values were significantly higher in RCC patients than in LCC patients (P = 5.9×10-8). Moreover, the expression of immune checkpoint targets was significantly higher in RCC patients than in LCC patients (P < 0.05), indicating that RCC patients maybe more sensitive to immunotherapy. However, LCC and RCC patients did not differ significantly in their sensitivity to eight selected chemicals or target drugs (P > 0.05). The average half-maximal inhibitory concentrations for camptothecin, teniposide, vinorelbine, and mitoxantrone were significantly lower in low-risk than in high-risk RCC patients (P < 0.05), indicating that the lower risk score of RCC patients, the more sensitive they were to these four drugs. Conclusions: We investigated the differences in prognosis, TIM, and drug treatment response between LCC and RCC patients, which may contribute to accurate colon cancer prognosis and treatment of colon cancer.
- 24 July 2023
- Published by Impact Journals, LLC in Aging
- Vol. 15 (14) , 7084-7097
Open AccessSevere pneumonia induces immunosenescence of T cells in the lung of mice
Background: In this study, we compared the prognosis, tumor immune microenvironment (TIM), and drug treatment response between left-sided (LCC) and right-sided (RCC) colon cancer to predict outcomes in patients with LCC and RCC. Methods: Based on identified differentially expressed genes and using single-cell RNA sequencing data, we constructed and validated a prognostic model for LCC and RCC patients in the TCGA-COAD cohort and GSE103479 cohort. Moreover, we compared the differences of TIM characteristics and drug treatment response between LCC and RCC patients. Results: We constructed and validated a five-gene prognostic model for LCC patients and a four-gene prognostic model for RCC patients, and both showed excellent performance. The RCC patients with higher risk scores were significantly associated with greater metastasis (P = 2.6×10-5), N stage (P = 0.012), advanced pathological stage (P = 1.4×10-4), and more stable microsatellite status (P = 0.007) but not T stage (P = 0.200). For LCC patients, the risk scores were not significantly associated with tumor stage and microsatellite status (P > 0.05). Additionally, immune infiltration by CD8 and regulatory T cells and M0, M1, and M2 macrophages differed significantly between LCC and RCC patients (P < 0.05). APC and TP53 mutations were significantly more common in LCC patients (P < 0.05). In contrast, KRAS, SYNE1, and MUC16 mutations were significantly more common in RCC patients (P < 0.05). In addition, tumor mutation burden values were significantly higher in RCC patients than in LCC patients (P = 5.9×10-8). Moreover, the expression of immune checkpoint targets was significantly higher in RCC patients than in LCC patients (P < 0.05), indicating that RCC patients maybe more sensitive to immunotherapy. However, LCC and RCC patients did not differ significantly in their sensitivity to eight selected chemicals or target drugs (P > 0.05). The average half-maximal inhibitory concentrations for camptothecin, teniposide, vinorelbine, and mitoxantrone were significantly lower in low-risk than in high-risk RCC patients (P < 0.05), indicating that the lower risk score of RCC patients, the more sensitive they were to these four drugs. Conclusions: We investigated the differences in prognosis, TIM, and drug treatment response between LCC and RCC patients, which may contribute to accurate colon cancer prognosis and treatment of colon cancer.
- Open Access
- 13 May 2023
- Published by Wiley in Cancer Reports
- Vol. 6 (6) , e1828
Identification of m6A‐related lncRNAs as prognostic signature within colon tumor immune microenvironment
Background: The current study probed prognosis‐related potential for m6A‐related lncRNAs signatures within colon tumor immune microenvironment (TIM).Methods: After downloading transcriptomic datasets for colon cancer (CC) patients from The Cancer Genome Atlas (TCGA), they were divided, in a 1:1 ratio, within training or test datasets. m6A‐related lncRNAs were then scrutinized across such dataset using Pearson correlation assessment before generating a m6A‐related lncRNAs prognosis‐related model using the training dataset. The latter was then validated with the test and the whole dataset. In addition, we compared the differences of TIM and the estimated IC50 of drug response between the high‐ and low‐risk groups.Results: Overall survival (OS) resulted as linked with 11 m6A‐related lncRNAs, while within the developed prognosis‐related model, areas‐under‐curves were as follows: within training dataset, values at 3‐, 4‐, and 5‐years were 0.777, 0.819, and 0.805, accordingly, and for test one, they were 0.697, 0.682, and 0.706, respectively. Finally, the values for the whole dataset were 0.675 (3‐year), 0.682 (4‐years), and 0.679 (5‐years), accordingly. Moreover, CC cases categorized within low‐risk cohort demonstrated enhanced OS (p < .0001), lower metastasis (p = 2e‐06) and lower T stage (p = .0067), more instability for microsatellite status (p = .012), and downregulation for PD‐L1, PD‐1, CTLA‐4, LAG3, and HAVCR2 (p < .05). In addition, risk scorings were significantly linked to the degree of infiltrative intensity for CD8 and CD4 (memory resting) T‐cells, T‐regulatory (Tregs), and Mast cells triggering (p < .05). Patients with low infiltrative propensity for CD4 T‐cells also had better OS (p = .016). Moreover, six representative drugs were found to be sensitive for treating CC patients.Conclusion: A robust m6A‐related prognostic model with great performances was developed before exploring the TIM characteristics and its potential therapeutic drugs, which might improve the prognosis and therapeutic efficacy.
- 13 May 2023
- Published by Wiley in Cancer Reports
- Vol. 6 (6) , e1828
Open AccessIdentification of m6A‐related lncRNAs as prognostic signature within colon tumor immune microenvironment
Background: The current study probed prognosis‐related potential for m6A‐related lncRNAs signatures within colon tumor immune microenvironment (TIM).Methods: After downloading transcriptomic datasets for colon cancer (CC) patients from The Cancer Genome Atlas (TCGA), they were divided, in a 1:1 ratio, within training or test datasets. m6A‐related lncRNAs were then scrutinized across such dataset using Pearson correlation assessment before generating a m6A‐related lncRNAs prognosis‐related model using the training dataset. The latter was then validated with the test and the whole dataset. In addition, we compared the differences of TIM and the estimated IC50 of drug response between the high‐ and low‐risk groups.Results: Overall survival (OS) resulted as linked with 11 m6A‐related lncRNAs, while within the developed prognosis‐related model, areas‐under‐curves were as follows: within training dataset, values at 3‐, 4‐, and 5‐years were 0.777, 0.819, and 0.805, accordingly, and for test one, they were 0.697, 0.682, and 0.706, respectively. Finally, the values for the whole dataset were 0.675 (3‐year), 0.682 (4‐years), and 0.679 (5‐years), accordingly. Moreover, CC cases categorized within low‐risk cohort demonstrated enhanced OS (p < .0001), lower metastasis (p = 2e‐06) and lower T stage (p = .0067), more instability for microsatellite status (p = .012), and downregulation for PD‐L1, PD‐1, CTLA‐4, LAG3, and HAVCR2 (p < .05). In addition, risk scorings were significantly linked to the degree of infiltrative intensity for CD8 and CD4 (memory resting) T‐cells, T‐regulatory (Tregs), and Mast cells triggering (p < .05). Patients with low infiltrative propensity for CD4 T‐cells also had better OS (p = .016). Moreover, six representative drugs were found to be sensitive for treating CC patients.Conclusion: A robust m6A‐related prognostic model with great performances was developed before exploring the TIM characteristics and its potential therapeutic drugs, which might improve the prognosis and therapeutic efficacy.